Nanoparticle light filtering method and apparatus
Implementations of the present invention relate to apparatuses, systems, and methods for blocking, attenuating, or filtering neuroactive wavelengths of the visible light spectrum and reducing or preventing the symptoms affiliated with exposure to those wavelengths. Nanoparticles of a predetermined composition, size, and structure are dispersed in a host medium to create an optical notch filter, thereby attenuating only a narrow range of the visible spectrum.
1. A method for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles, the method comprising:
receiving an amount of light across a visible spectrum;
introducing an optical filter to the path of the light, the optical filter comprising a plurality of nanoparticles dispersed within a host material, wherein a concentration of the plurality of nanoparticles in the host material is about 15% weight to volume, about 20% weight to volume, or about 7.05×10 10 particles per cubic centimeter; and
attenuating a portion of the spectrum associated with absorption by melanopsin ganglion cells such that a figure of merit greater than 1 is achieved, wherein the figure of merit is defined as a ratio of attenuation of light weighted across an action potential spectrum of a melanopsin pathway to attenuation of light weighted across a visual spectral response.
2. The method of claim 1 , wherein the plurality of nanoparticles exhibit local surface plasmon resonance when exposed to the portion of the spectrum associated with absorption by melanopsin ganglion cells.
3. The method of claim 1 , wherein attenuating a portion of the spectrum comprises attenuating light having a central wavelength of 480 nm, 590 nm, or 620 nm.
4. The method of claim 3 , wherein the optical filter has a full width half maximum of less than 100 nm at the central wavelength.
5. The method of claim 3 , wherein the optical filter has a full width half maximum of greater than 50 nm and less than 100 nm at the central wavelength.
6. The method of claim 3 , wherein the optical filter has a full width half maximum of greater than 50 nm and less than 80 nm at the central wavelength.
7. The method of claim 1 , wherein a figure of merit greater than 1.5 is achieved.
8. A method for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles, the method comprising:
receiving an amount of light across a visible spectrum;
introducing an optical filter to the path of the light, the optical filter comprising a plurality of nanoparticles dispersed within a host material such that the optical filter is configured to attenuate light having a central wavelength of 480 nm, 590 nm, or 620 nm, wherein the plurality of nanoparticles have a concentration in the host medium of about 15% to 20% weight to volume; and
attenuating light at the central wavelength such that a figure of merit greater than 1.5 is achieved, wherein the figure of merit is defined as a ratio of attenuation of light weighted across an action potential spectrum of a melanopsin pathway to attenuation of light weighted across a visual spectral response.
9. The method of claim 8 , wherein the optical filter has a full width half maximum of greater than 50 nm and less than 100 nm at the central wavelength.
10. The method of claim 8 , wherein the optical filter has a full width half maximum of 80 nm at the central wavelength.
11. A method for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles, the method comprising:
receiving an amount of light across a visible spectrum;
introducing an optical filter to the path of the light, the optical filter comprising a plurality of nanoparticles dispersed within a host material, wherein the concentration of the plurality of nanoparticles in the host material is about 7.05×10 10 particles per cubic centimeter; and
attenuating a portion of the spectrum associated with absorption by melanopsin ganglion cells such that a figure of merit greater than 1 is achieved, wherein the figure of merit is defined as a ratio of attenuation of light weighted across an action potential spectrum of a melanopsin pathway to attenuation of light weighted across a visual spectral response.
12. The method of claim 11 , wherein the plurality of nanoparticles exhibit local surface plasmon resonance when exposed to the portion of the spectrum associated with absorption by melanopsin ganglion cells.
13. The method of claim 11 , wherein attenuating a portion of the spectrum comprises attenuating light having a central wavelength of 480 nm, 590 nm, or 620 nm.
14. The method of claim 13 , wherein the optical filter has a full width half maximum of less than 100 nm at the central wavelength.
15. The method of claim 13 , wherein the optical filter has a full width half maximum of greater than 50 nm and less than 100 nm at the central wavelength.
16. The method of claim 13 , wherein the optical filter has a full width half maximum of greater than 50 nm and less than 80 nm at the central wavelength.
17. The method of claim 11 , wherein a figure of merit greater than 1.5 is achieved.